Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $455.45, denoting a -1% move from the preceding trading day.

The stock's fall snapped a three-day winning streak.

The biotech, known as the developer of the first CRISPR drug, will consolidate sites in the state as it stops developing a diabetes cell therapy.